This special episode from ACC.18 features an interview with Erik Magnus Ohman, Roger S. Blumenthal, and Philippe Gabriel Steg about Cardiovascular Outcomes with Alirocumab After Acute Coronary Syndrome: Results of the ODYSSEY Outcomes Trial.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Keywords: ACC18, ACC Annual Scientific Session, Acute Coronary Syndrome, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins B, Brain Ischemia, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Cost-Benefit Analysis, Diabetes Mellitus, Dyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Myocardial Infarction, Myocardial Revascularization, Secondary Prevention, Stroke, Treatment Outcome, Metabolic Syndrome, Thoracic Surgery, Heart Failure, Angiography, ACCELLite

< Back to Listings